Found: 20
Select item for more details and to access through your institution.
Identification of a distinct population of CD133<sup>+</sup>CXCR4<sup>+</sup> cancer stem cells in ovarian cancer.
- Published in:
- Scientific Reports, 2015, p. 10357, doi. 10.1038/srep10357
- By:
- Publication type:
- Article
CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 21, p. 3340, doi. 10.3390/cells11213340
- By:
- Publication type:
- Article
CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells.
- Published in:
- Cell Death & Disease, 2019, v. 10, n. 8, p. N.PAG, doi. 10.1038/s41419-019-1796-6
- By:
- Publication type:
- Article
New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM.
- Published in:
- Vaccines, 2020, v. 8, n. 2, p. 164, doi. 10.3390/vaccines8020164
- By:
- Publication type:
- Article
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.
- Published in:
- International Journal of Molecular Sciences, 2016, v. 17, n. 5, p. 790, doi. 10.3390/ijms17050790
- By:
- Publication type:
- Article
Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211011455
- By:
- Publication type:
- Article
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/1758835921989223
- By:
- Publication type:
- Article
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 12, p. 2016, doi. 10.1038/s41416-024-02702-x
- By:
- Publication type:
- Article
Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0074548
- By:
- Publication type:
- Article
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/1758835921989223
- By:
- Publication type:
- Article
Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211011455
- By:
- Publication type:
- Article
Inhibition of stromal CXCR4 impairs development of lung metastases.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 10, p. 1713, doi. 10.1007/s00262-012-1223-7
- By:
- Publication type:
- Article
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.
- Published in:
- Cancers, 2022, v. 14, n. 7, p. 1849, doi. 10.3390/cancers14071849
- By:
- Publication type:
- Article
New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 7, p. 1952, doi. 10.3390/cancers12071952
- By:
- Publication type:
- Article
High-Frequency Ultrasound-Guided Injection for the Generation of a Novel Orthotopic Mouse Model of Human Thyroid Carcinoma.
- Published in:
- Thyroid, 2016, v. 26, n. 4, p. 552, doi. 10.1089/thy.2015.0511
- By:
- Publication type:
- Article
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.
- Published in:
- International Journal of Cancer, 2014, v. 135, n. 2, p. 379, doi. 10.1002/ijc.28689
- By:
- Publication type:
- Article
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2019, v. 38, n. 1, p. 1, doi. 10.1186/s13046-019-1420-8
- By:
- Publication type:
- Article
Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2018, v. 37, n. 1, p. N.PAG, doi. 10.1186/s13046-018-0952-7
- By:
- Publication type:
- Article
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
- Published in:
- 2017
- By:
- Publication type:
- journal article